We examined the methylation status of CCGG sites in hepatitis B virus (HBV) DNA to determine whether methylation could be responsible for the selective expression of the HBV surface gene in chronic hepatitis B infection and hepatocellular carcinoma. Infected liver tissue from patients with low levels of viral replication was analyzed for HBV DNA copy number per haploid cell genome. Total cellular DNA, with sufficient HBV DNA, was digested with the restriction endonucleases Msp I and Hpa II, to determine whether the HBV DNA was methylated, or HindIll, to determine whether the HBV DNA was integrated or episomal. The cleavage fragments were analyzed by Southern blotting and hybridization to 32P-labeled HBV DNA. In replicative chronic hepatitis B, hypomethylation of the HBV genome correlated with HBV expression in both virions and infected tissue. In carriers with nonreplicative infection, it was difficult to ascertain the role of methylation as copy number was low. HBV DNA copy number was also low in 17 out of 29 of the tumor tissues tested and as many as 14 out of 16 of the adjacent nonneoplastic tissues tested. Integrated sequences were hypermethylated in the PLC/PRF/5 cell line and in six of the tumor tissues suggesting that methylation plays a role in HBV gene repression. However, since DNA from five other tumors was hypomethylated, the belief that methylation per se is an absolute determinant of HBV core gene repression does not hold for human hepatocellular carcinoma tissue. Additional factors, such as gene rearrangements, therefore, must influence HBV expression in hepatocellular carcinoma.
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Chronic hepatitis B carriers may either have predominantly "replicative" or "nonreplicative" hepatitis B virus (HBV) infection (1) . Chronically infected carriers with replicative infection evolve after several years from an early replicative phase to a later, predominantly nonreplicative phase in which HBV expression is diminished. In carriers with replicative infection, HBV DNA in liver exists as several episomal replicative intermediates. Both the core and surface genes are transcribed from episomal HBV DNA, intact virions are assembled and thus high levels of hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) are present in serum. HBeAg is thought to be a breakdown product of the hepatitis B core antigen (2) . The majority of long-standing HBV carriers and patients with HBV-related hepatocellular carcinoma (HCC) have low levels of HBV replication (3) (4) (5) .
Their serum is positive for HBsAg and antibody to HBeAg (anti-HBe) but negative for HBeAg, HBV DNA polymerase, and HBV DNA, indicating the absence of viral assembly; HBV DNA in liver is predominantly integrated (6) . Transcription of integrated HBV sequences is assumed to be the source of HBsAg in these carriers (7) . The human HCC cell line PLC/PRF/5 contains only integrated HBV DNA sequences and expresses only HBsAg (8) .
Methylation of specific cytosine bases has been implicated in gene repression in viral infections (9) (10) (11) . In particular, two studies (12, 13) have suggested that core antigen expression is regulated by methylation. Yoakum et al. (12) succeeded in expressing HBV core gene after 5'-azacytidine treatment of transfected human cell lines. This suggested that methylation was responsible for the repression since 5'-azacytidine inhibits methylation in two steps: it is incorporated into replicating DNA and inhibits methyltransferase (14) . Miller and Robinson (13) fragment, Boehringer Mannheim) followed by a reverse transcriptase (Boehringer Mannheim) reaction using the protocol of Sattler and Robinson (15) .
Restriction Endonuclease Mapping. Each DNA sample was digested with restriction endonucleases Hpa II (Boehringer Mannheim) and Msp I (New England Biolabs). Both enzymes cut the sequence CCGG, but methylation of the internal cytosine base rendered the sequence resistant to Hpa II endonuclease digestion but not to Msp I digestion (16) . Since HBV DNA does not contain a HindIII site, integration of HBV DNA into total cellular DNA was examined by digestion of total cellular DNA with HindIII (Boehringer Mannheim). Completeness of digestion was monitored by adding 1 ,ug of 4X174 DNA (New England Nuclear) to a 10-,ul aliquot of each reaction mixture and verifying by electrophoresis that the appropriate phage cleavage products were present. After digestion, the DNA was loaded into the slots of a 1% agarose gel and electrophoresed at 30 V overnight. Two to 20 jig of total cellular DNA per gel lane was used, depending on the copy number of HBV DNA per genome. The DNA was transferred to a nitrocellulose filter by the method of Southern (17, 18) . The filter was then hybridized to labeled, nick-translated pAM12 HBV DNA (19) for 24 hr at 370C in 50% (vol/vol) formamide, 5 x SSC (1 x SSC = 0.15 M NaCl/ 0.015 M sodium citrate, pH 7.0.), 1x Denhardt's (0.02% each of Ficoll/polyvinyl pyrrolidone/bovine serum albumin in 3 x SSC), 20 mM sodium phosphate buffer (pH 6.5), 10% (wt/vol) sodium dextran sulphate, and denatured carrier DNA at 100 ,ug/ml. Hepatitis B probe for these studies, pAM12 (a gift from the laboratory of J. Gerin, Rockville, MD), was purified by electroelution and labeled by nicktranslation to high specific activity (1-2 x 108 dpm/,g) using
The filter was washed five times at 65°C with 2x SSC in 0.1% NaDodSO4, washed three times at 370C with 0.1x SSC in 0.1% NaDodSO4, and then autoradiographed for 2-7 days at -70°C using an intensifying screen.
Copy Number Screening. DNA from nonreplicative carriers was screened for HBV copy number per genome by spotting total cellular DNA onto a nitrocellulose filter in increasing concentrations (1-25 ug) together with purified HBV DNA (1-100 pg), as a calibrated standard. As a control, PLC/PRF/5 DNA was also included as it has a known copy number of four to six genomes per haploid mammalian cell DNA equivalent (8, 20) . After hybridization, washing, and autoradiography, the HBV DNA copy number was measured by cutting out the circles on the filter, measuring the radioactivity by scintillation counting, and constructing a standard curve. The amount of HBV DNA in pg per mg of total cellular DNA was extrapolated from the standard curve and from this the copy number was calculated. Southern blots were performed whenever the copy number was found to be ¢0.2 so as not to exclude any specimens amenable to further study.
RESULTS
Two of the 39 subjects were HBsAg negative. One of these, 1T, was included in the study as copy number was sufficient to enable Southern blot analysis. Four of the carriers studied were HBeAg-positive and had a high copy number of HBV DNA. In only one anti-HBe-positive carrier did the HBV DNA copy number permit Southern blot analysis (Table 1) . Seventy-nine percent (7/9) of the serum HBeAg-positive HCC specimens and one-half (10/20) of the serum HBeAgnegative HCC tissues could be analyzed. The majority of non-neoplastic tissues from patients with HCC had a copy number <1, thus, only one gave a blot that could be analyzed (Table 2) .
Total cellular DNA with sufficient HBV DNA was digested with HindIII to determine whether the HBV DNA was episomal or integrated. All the HBeAg-positive carriers studied had only episomal HBV DNA. The HBeAg-negative carrier studied had both integrated and episomal HBV DNA. Two serum HBeAg-negative HCC tissues had detectable episomal HBV DNA, but integrated copies were not visible in the Southern blot. In the remaining seven serum HBeAgnegative HCC tissues only integrated HBV DNA was detected. Two of the serum HBeAg-positive HCC tissues showed both episomal and integrated HBV DNA, while in the other two samples, only integrated HBV DNA was detected. Four tumors were omitted from the integration analysis as poor quality DNA obscured their integration status.
Methylation. The restriction patterns after digestion with Hpa II and Msp I were compared. Fewer bands and larger molecular weight fragments obtained after digestion with Hpa II indicated CCGG site methylation and hence resistance to Hpa II digestion. All the HBeAg-positive carriers had identical Hpa II and Msp I lanes, indicating that the viral DNA was not methylated (Fig. 1) .
In long-standing, nonreplicative, chronic hepatitis B, viral DNA copy number was frequently low, and the role of methylation in influencing HBV gene expression was, therefore, difficult to ascertain (Table 1) . For this reason the DNA from tissue of HBV-related HCC patients was studied in the expectation that clonal amplification of cells bearing HBV DNA would make analysis feasible. All HCC specimens were initially regarded as being representative of low viral expression since most patients with HCC have predominantly nonreplicative infection (3) (4) (5) . Also, there is evidence to suggest a certain level of gene control in HCC (7) .
Six tumor tissues showed hypermethylation of HBV DNA. Three of these were serum HBeAg-positive (Fig. 2) , and one of these did show traces of episomal HBV DNA. these, iT, was the special case mentioned above: this patient was serum HBsAg-negative. Two of the others showed predominantly episomal DNA. Thus, if the restriction pattern seen is that of the episomal HBV DNA, one would expect these not to be methylated (Fig. 3) . One, however, appeared to have only integrated sequences and these were hypomethylated. The fifth hypomethylated tumor was from an HBeAgpositive patient who had both episomal and integrated HBV DNA. Two tumors were excluded from the methylation study as their methylation status was not clear. 1 HBeAg expression was detected in only one of the five hypomethylated HCC specimens. Expression of HBeAg in this HCC patient could not be attributed solely to the hypomethylated integrated sequences as episomal sequences were also present. The five hypomethylated HCC specimens included the special case that was serum HBsAg negative. A further two tumors were unusual in that they were HBeAg negative with only episomal HBV DNA detectable; no integrated sequences were visible. Thus, although the HBV DNA was hypomethylated in both of these patients, this would be expected if only the episomal sequences were visualized. The fifth hypomethylated tissue did not express the HBeAg, only integrated HBV DNA sequences were detected, and these were not methylated. Since all HCC with integrated HBV DNA did not have hypermethylated HBV DNA, our results suggest that methylation per se is not an absolute determinant of gene expression in HCC tissue. Thus, other factors, such as gene rearrangements, regulatory gene disruption or reading frame shifts must also be considered as possible influences of HBV expression in chronic hepatitis B and HCC.
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